A Study Inhibiting Telomerase to Reverse Trastuzumab Resistance in HER2+ Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: GRN163L in combination with trastuzumab
Sponsor: Indiana University
Collaborators: Breast Cancer Research Foundation|Geron Corporation